| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Samsara BioCapital, L.P. | 9.9% | 0% | $12,001,117 | +$1,803,961 | 403,942 | +18% | Srinivas Akkaraju | 08 Dec 2025 |
| Invus Global Management, LLC | 9.4% | -5.9% | $9,179,310 | +$1,051,154 | 393,098 | +13% | Raymond Debbane | 30 Sep 2025 |
| Trails Edge Capital Partners, LP | 9.9% | $5,108,040 | 340,536 | Trails Edge Capital Partners, LP | 29 Aug 2025 |
As of 31 Dec 2025, 16 institutional investors reported holding 300,228 shares of vTv Therapeutics Inc. - Class A Common Stock, par value $0.01 per share (VTVT). This represents 7.4% of the company’s total 4,080,222 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 300,228 | $12,005,747 | +$2,640,639 | $39.99 | 16 |
| 2025 Q3 | 988,279 | $23,052,921 | +$9,364,357 | $23.35 | 23 |
| 2025 Q2 | 587,143 | $8,742,344 | +$226,154 | $15.00 | 21 |
| 2025 Q1 | 571,712 | $9,902,095 | +$353,201 | $17.32 | 20 |
| 2024 Q4 | 551,416 | $7,570,090 | +$133,643 | $13.81 | 17 |
| 2024 Q3 | 542,324 | $7,337,088 | +$2,516,893 | $13.56 | 20 |
| 2024 Q2 | 348,140 | $6,148,038 | +$252,272 | $17.66 | 19 |
| 2024 Q1 | 333,650 | $7,850,341 | +$6,240,904 | $23.53 | 19 |
| 2023 Q4 | 68,620 | $788,715 | +$781,835 | $11.50 | 14 |
| 2023 Q3 | 600 | $287 | +$287 | $0.48 | 1 |